Singapore markets closed

Bio-Rad Laboratories, Inc. (BIO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
527.30+0.44 (+0.08%)
At close: 4:04PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close526.86
Open524.10
Bid0.00 x 800
Ask0.00 x 800
Day's range521.74 - 530.25
52-week range309.38 - 540.06
Volume137,272
Avg. volume280,817
Market cap15.64B
Beta (5Y monthly)1.07
PE ratio (TTM)8.17
EPS (TTM)64.50
Earnings date29 Oct 2020 - 02 Nov 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est603.75
  • The United States Court of Appeals for the Federal Circuit Affirms That 10x Genomics Willfully Infringed Bio-Rad U.S. Patent and Upholds Lower Court’s Award of Damages
    Business Wire

    The United States Court of Appeals for the Federal Circuit Affirms That 10x Genomics Willfully Infringed Bio-Rad U.S. Patent and Upholds Lower Court’s Award of Damages

    Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that the United States Court of Appeals for the Federal Circuit today affirmed that 10x Genomics willfully infringed U.S. Patent 8,889,083, exclusively licensed to Bio-Rad from the University of Chicago. The Appeals Court upheld the lower Court’s finding on monetary damages amounting to $23.9 million at the time of the trial, November 2018, awarding Bio-Rad a 15 percent royalty on past and future sales, and a permanent injunction against 10x’s Single Cell 3’ Gene Expression products, Single Cell ATAC-seq products, and Single Cell V(D)J products that were found to infringe the ‘083 patent.

  • Bio-Rad Laboratories Inc (BIO) (BIO.B) Q2 2020 Earnings Call Transcript
    Motley Fool

    Bio-Rad Laboratories Inc (BIO) (BIO.B) Q2 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to the Q2 2020 Bio-Rad Laboratories, Inc. Earnings Conference Call. Before we begin our review, I would like to caution everyone that we will be making forward-looking statements about management's goals, plans and expectations, our future financial performance and other matters.

  • Bio-Rad (BIO) Q2 Earnings Beat Estimates, Gross Margin Rises
    Zacks

    Bio-Rad (BIO) Q2 Earnings Beat Estimates, Gross Margin Rises

    Bio-Rad's (BIO) second-quarter 2020 results reflect strong performance by the Life Sciences segment, boosted by coronavirus-led increased testing demand.